Literature DB >> 27188289

Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone.

Neslihan Önenli Mungan1, Dinçer Yıldızdaş2, Deniz Kör2, Özden Özgür Horoz2, Faruk İncecik2, Murat Öktem3, Johannes Sander4.   

Abstract

Tyrosinemia type I is an autosomal recessively inherited metabolic disease of tyrosine metabolism due to the deficiency of fumarylacetoacetate hydrolase. Clinical manifestations include hepatic failure, cirrhosis, hepatocellular carcinoma, renal fanconi syndrome, and neurologic crisis. With the introduction of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione treatment the prognosis improved with reduced rate of complications. "Neurologic crisis" of tyrosinemia type I is a rare complication seen after discontinuation of treatment characterized with anorexia, vomiting, and hyponatremia in the initial phase continuing with paresthesia and paralysis of the extremities and the diaphragm. Here, we report a tyrosinemia type I patient who admitted to the hospital with nonspecific symptoms such as vomiting, anorexia, weakness, and restlessness only after one month discontinuation of nitisone and diagnosed as neurological crisis.

Entities:  

Keywords:  Neurologic crisis; Nitisone; Polyneuropathy; Tyrosinemia type I

Mesh:

Substances:

Year:  2016        PMID: 27188289     DOI: 10.1007/s11011-016-9833-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  7 in total

1.  Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.

Authors:  Maria Luz Couce; Jaime Dalmau; Mireia del Toro; Guillem Pintos-Morell; Luís Aldámiz-Echevarría
Journal:  Pediatr Int       Date:  2011-12       Impact factor: 1.524

2.  Hematin therapy for the neurologic crisis of tyrosinemia.

Authors:  J M Rank; A Pascual-Leone; W Payne; M Glock; D Freese; H Sharp; J R Bloomer
Journal:  J Pediatr       Date:  1991-01       Impact factor: 4.406

3.  Neurological crisis in hereditary tyrosinaemia and complete reversal after liver transplantation.

Authors:  G Noble-Jamieson; N Jamieson; P Clayton; S Bailey; M Ryalls; N D Barnes
Journal:  Arch Dis Child       Date:  1994-06       Impact factor: 3.791

4.  Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  S Lindstedt; E Holme; E A Lock; O Hjalmarson; B Strandvik
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

5.  Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.

Authors:  Jean Larochelle; Fernando Alvarez; Jean-François Bussières; Isabelle Chevalier; Louis Dallaire; Josée Dubois; Frédéric Faucher; Daphna Fenyves; Paul Goodyer; André Grenier; Elisabeth Holme; Rachel Laframboise; Marie Lambert; Sven Lindstedt; Bruno Maranda; Serge Melançon; Aicha Merouani; John Mitchell; Guy Parizeault; Luc Pelletier; Véronique Phan; Piero Rinaldo; C Ronald Scott; Charles Scriver; Grant A Mitchell
Journal:  Mol Genet Metab       Date:  2012-07-13       Impact factor: 4.797

6.  Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.

Authors:  J-U Schlump; C Perot; K Ketteler; M Schiff; E Mayatepek; U Wendel; U Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2008-05-20       Impact factor: 4.982

7.  Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.

Authors:  A Cigdem Aktuglu Zeybek; Ertugrul Kiykim; Erdogan Soyucen; Serif Cansever; Suheyla Altay; Tanyel Zubarioglu; Tulay Erkan; Ahmet Aydin
Journal:  Pediatr Int       Date:  2014-12-11       Impact factor: 1.524

  7 in total
  4 in total

1.  Unusual first presentation of a metabolic disorder.

Authors:  Claire Emma Strauss; Gayle Hann
Journal:  BMJ Case Rep       Date:  2019-03-22

2.  Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.

Authors:  Ayse Cigdem Aktuglu Zeybek; Ertugrul Kiykim; Salim Neselioglu; Halise Zeynep Iscan; Tanyel Zubarioglu; Mehmet Serif Cansever; Ozcan Erel
Journal:  Pediatr Res       Date:  2021-10-09       Impact factor: 3.953

3.  Severe neurological crisis in adult patients with Tyrosinemia type 1.

Authors:  Charlotte Dawson; Radha Ramachandran; Samreen Safdar; Elaine Murphy; Orlando Swayne; Jonathan Katz; Philip N Newsome; Tarekegn Geberhiwot
Journal:  Ann Clin Transl Neurol       Date:  2020-08-21       Impact factor: 4.511

Review 4.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.